Last reviewed · How we verify
Symbicort Turbuhaler forte
At a glance
| Generic name | Symbicort Turbuhaler forte |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
Key clinical trials
- A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma (PHASE4)
- Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler (PHASE1)
- Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte (PHASE1)
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PHASE3)
- Pharmacokinetic Pilot Study on Budesonide/Formoterol (NA)
- Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler (PHASE1)
- Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers (PHASE1)
- Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort Turbuhaler forte CI brief — competitive landscape report
- Symbicort Turbuhaler forte updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI